溃疡性结肠炎和克罗恩病饮食的个体化研究:一系列N-of-1饮食试验
在19个中心招募7-18岁活动性炎症的炎症性肠病患者,开展54项单受试者双交叉N-of-1试验,比较特定碳水化合物饮食(SCD)与改良SCD(MSCD)及各自与基线常规饮食。结果显示SCD与MSCD在多数个体中表现相似,平均无临床意义差异,部分个体症状和粪钙卫蛋白较常规饮食改善,但整体未一致改善。
要点
- SCD与MSCD在多数个体中表现相似,平均临床意义差异概率<1%。
- SCD与MSCD的粪钙卫蛋白几何均值比值无显著差异(0.77,95%可信区间0.51,1.10)。
- 部分个体症状和粪钙卫蛋白较常规饮食改善,但整体未一致改善。
核心结论
- SCD和MSCD未一致改善症状或炎症,尽管部分个体可能获益。
- 饮食变化研究存在固有困难,复杂化研究设计并最终影响有效性结论。
研究设计与样本
- 54项单受试者双交叉N-of-1试验,在19个中心招募7-18岁活动性炎症的炎症性肠病患者。
- 患者经2周基线常规饮食后随机分配至2种序列之一,接受4个交替的8周SCD和MSCD干预期。
主要发现
- 21名(39%)参与者完成试验,9名(17%)完成单次交叉,24名(44%)退出。
- 退出或提前完成常见:缺乏应答(n=11)、不良事件(n=11)、不愿继续(n=6)。
- SCD与MSCD在多数个体中表现相似,平均临床意义差异概率<1%。
- 平均治疗差异为-0.3(95%可信区间-1.2,0.75)。
- 粪钙卫蛋白几何均值比值SCD与MSCD比较无显著差异(0.77,95%可信区间0.51,1.10)。
关键数值与推荐
- SCD与MSCD比较,IBD症状临床意义差异的贝叶斯后验概率<1%。
- 平均治疗差异-0.3(95%可信区间-1.2,0.75)。
- 粪钙卫蛋白几何均值比值0.77(95%可信区间0.51,1.10),无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 饮食变化研究存在固有困难,复杂化研究设计并最终影响有效性结论。
- 退出或提前完成常见:缺乏应答(n=11)、不良事件(n=11)、不愿继续(n=6)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Evidence about specific carbohydrate diet (SCD) for inflammatory bowel disease (IBD) is limited. We conducted 54 single-subject, double-crossover N-of-1 trials comparing SCD with a modified SCD (MSCD) and comparing each with the participant's baseline, usual diet (UD). METHODS: Across 19 sites, we recruited patients aged 7-18 years with IBD and active inflammation. Following a 2-week baseline (UD), patients were randomized to 1 of 2 sequences of 4 alternating 8-week SCD and MSCD periods. Outcomes included fecal calprotectin and patient-reported symptoms. We report posterior probabilities from Bayesian models comparing diets. RESULTS: Twenty-one (39%) participants completed the trial, 9 (17%) completed a single crossover, and 24 (44%) withdrew. Withdrawal or early completion occurred commonly (lack of response [n = 11], adverse events [n = 11], and not desiring to continue [n = 6]). SCD and MSCD performed similarly for most individuals. On average, there was <1% probability of a clinically meaningful difference in IBD symptoms between SCD and MSCD. The average treatment difference was -0.3 (95% credible interval -1.2, 0.75). There was no significant difference in the ratio of fecal calprotectin geometric means comparing SCD and MSCD (0.77, 95% credible interval 0.51, 1.10). Some individuals had improvement in symptoms and fecal calprotectin compared with their UD, whereas others did not. DISCUSSION: SCD and MSCD did not consistently improve symptoms or inflammation, although some individuals may have benefited. However, there are inherent difficulties in examining dietary changes that complicate study design and ultimately conclusions regarding effectiveness.
引用
- Kaplan HC, Opipari-Arrigan L, Yang J, et al. Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease: A Series of N-of-1 Diet Trials. Am J Gastroenterol. 2022. PMID: 35442220. doi:10.14309/ajg.0000000000001800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。